{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:40:06Z","timestamp":1786992006333,"version":"build-2736575974"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jdin.2025.05.023","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T04:36:28Z","timestamp":1759552588000},"page":"9-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Originator versus biosimilar adalimumab in hidradenitis suppurativa: A multicenter real-world analysis of clinical response, maintenance of response, and switching"],"prefix":"10.1016","volume":"24","author":[{"given":"Marra","family":"Aghajani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Sholji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Burrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Frew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jdin.2025.05.023_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life","volume":"35","author":"Nguyen","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"23","key":"10.1016\/j.jdin.2025.05.023_bib2","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.3390\/jcm11237240","article-title":"Current medical and surgical treatment of hidradenitis suppurativa-a comprehensive review","volume":"11","author":"Ocker","year":"2022","journal-title":"J Clin Med"},{"issue":"22","key":"10.1016\/j.jdin.2025.05.023_bib3","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1001\/jama.2019.16275","article-title":"Adalimumab and the challenges for biosimilars","volume":"322","author":"Gellad","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jdin.2025.05.023_bib4","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjd.16890","article-title":"Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches","volume":"179","author":"Blauvelt","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdin.2025.05.023_bib5","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.2147\/CCID.S478840","article-title":"The efficacy and safety of biosimilars in hidradenitis suppurativa: a comprehensive review","volume":"17","author":"Almukhadeb","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"12","key":"10.1016\/j.jdin.2025.05.023_bib6","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1111\/jdv.17598","article-title":"Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study","volume":"35","author":"Gulliver","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jdin.2025.05.023_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1359-6349(13)70001-6","article-title":"Clinical considerations for biosimilar antibodies","volume":"11","author":"Mellstedt","year":"2013","journal-title":"EJC Suppl"},{"issue":"11","key":"10.1016\/j.jdin.2025.05.023_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15803","article-title":"Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: what's beyond cost-effectiveness?","volume":"35","author":"Roccuzzo","year":"2022","journal-title":"Dermatol Ther"},{"issue":"10","key":"10.1016\/j.jdin.2025.05.023_bib9","first-page":"1518","article-title":"Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response-data from the German HS registry HSBest","volume":"12","author":"Kirsten","year":"2022","journal-title":"Life (Basel)"},{"issue":"4","key":"10.1016\/j.jdin.2025.05.023_bib10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3390\/jcm11041007","article-title":"Switching from adalimumab originator to biosimilar: clinical experience in patients with hidradenitis suppurativa","volume":"11","author":"Montero-Vilchez","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jdin.2025.05.023_bib11","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jdin.2025.05.023_bib12","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14387","article-title":"Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa","volume":"33","author":"Ricceri","year":"2020","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.jdin.2025.05.023_bib13","doi-asserted-by":"crossref","first-page":"745","DOI":"10.4103\/ijdvl.IJDVL_232_18","article-title":"Low-dose adalimumab biosimilar (ZRC-3197) in the treatment of hidradenitis suppurativa","volume":"84","author":"Patil","year":"2018","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"10","key":"10.1016\/j.jdin.2025.05.023_bib14","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.3390\/biomedicines10102522","article-title":"Adalimumab originator vs. biosimilar in hidradenitis suppurativa: a multicentric retrospective study","volume":"10","author":"Burlando","year":"2022","journal-title":"Biomedicines"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328725001105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328725001105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T08:39:48Z","timestamp":1770626388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328725001105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":14,"alternative-id":["S2666328725001105"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2025.05.023","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Originator versus biosimilar adalimumab in hidradenitis suppurativa: A multicenter real-world analysis of clinical response, maintenance of response, and switching","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2025.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}